Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031230289

Enrollment

1300

Registered

2023-08-12

Start date

2005-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have prescription of prasugrel or clopidogrel within the enrollment period (December 24, 2021 to September 23, 2024). The cohort entry date: first prescription date of prasugrel or clopidogrel within the enrollment period. 2) Patients with acute ischemic stroke treated in hospital have diagnosis of atherothrombotic stroke or lacunar stroke during the past 30 days from the cohort entry date. 3) Patients who have risk factors for ischemic stroke recurrence. 4) The month 90 days prior to the cohort entry date is in the month following the observation start date (Look back period).

Exclusion criteria

Exclusion criteria: 1) Patients who have prescription of prasugrel or clopidogrel in the look back period. 2) No medical records from the day after the cohort entry date. 3) Patients who have prescriptions of prasugrel and clopidogrel on the cohort entry date.

Design outcomes

Primary

Measure	Time frame
Ischemic stroke recurrence	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-362251059

Outcome results